Close
  • Home

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

CAR-T Digest - August 2020

Funding

Deals  ·  Weekly Digest - 06 June to 12 June 2026
AmMax Bio licenses antibody-drug conjugate technology for Hematological cancers from Lonza

Weekly Digest – June 2026 Weekly Digest – June 2026 09 June 2026: AmMax Bio licenses antibody-drug conjugate technology for Hematological cancers from Lonza AmMax Bio has entered into a licensing agreement with Lonza to access its clinically validated antibody-drug […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 06 June to 12 June 2026
Johnson & Johnson to acquire Firefly Bio to expand oncology pipeline with degrader ADC platform

Weekly Digest – June 2026 Weekly Digest – June 2026 08 June 2026: Johnson & Johnson to acquire Firefly Bio to expand oncology pipeline with degrader ADC platform Johnson & Johnson has entered into a definitive agreement to acquire Firefly […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 30 May to 05 June 2026
Innovent Biologics’ IBI343 met primary endpoint in phase 3 Gastric cancer trial with NDA accepted by NMPA

Weekly Digest – June 2026 Weekly Digest – June 2026 04 June 2026: Innovent Biologics’ IBI343 met primary endpoint in phase 3 Gastric cancer trial with NDA accepted by NMPA Innovent Biologics has announced that IBI343, a CLDN18.2-targeted antibody-drug conjugate, […]

by Sandhya Ramalingam

Continue Reading
Regulatory  ·  Weekly Digest - 30 May to 05 June 2026
SOTIO receives U.S. FDA Orphan Drug Designation for SOT106, a potential best-in-class ADC for Sarcoma

Weekly Digest – June 2026 Weekly Digest – June 2026 03 June 2026: SOTIO receives U.S. FDA Orphan Drug Designation for SOT106, a potential best-in-class ADC for Sarcoma SOTIO announced that the U.S. FDA has granted Orphan Drug Designation to […]

by Sandhya Ramalingam

Continue Reading
Clinical  ·  Weekly Digest - 30 May to 05 June 2026
MediLink Therapeutics announces B7-H3 ADC YL201 met primary endpoint in phase 3 Nasopharyngeal carcinoma study

Weekly Digest – June 2026 Weekly Digest – June 2026 30 May 2026: MediLink Therapeutics announces B7-H3 ADC YL201 met primary endpoint in phase 3 Nasopharyngeal carcinoma study MediLink Therapeutics has announced that its B7-H3-targeted ADC YL201, successfully met the […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 30 May to 05 June 2026
Stipple Bio enters multi-target license agreement with Lonza to advance precision oncology ADC therapies

Weekly Digest – June 2026 Weekly Digest – June 2026 04 June 2026: Stipple Bio enters multi-target license agreement with Lonza to advance precision oncology ADC therapies Stipple Bio has strengthened its position in the next wave of ADC innovation […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 30 May to 05 June 2026
Mabion and KriSan Biotech sign letter of intent to explore ADC collaboration supporting strategic ambitions

Weekly Digest – June 2026 Weekly Digest – June 2026 01 June 2026: Mabion and KriSan Biotech sign letter of intent to explore ADC collaboration supporting strategic ambitions advanced Solid tumor study Mabion and KriSan Biotech have signed a Letter […]

by Sandhya Ramalingam

Continue Reading
Deals  ·  Weekly Digest - 30 May to 05 June 2026
Ratio Therapeutics and PharmaLogic expand manufacturing collaboration to support clinical development of [Ac-225]RTX-2358

Weekly Digest – June 2026 Weekly Digest – June 2026 29 May 2026: Ratio Therapeutics and PharmaLogic expand manufacturing collaboration to support clinical development of [Ac-225]RTX-2358 Ratio Therapeutics and PharmaLogic have expanded their manufacturing collaboration to support the clinical development […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 23 May to 29 May 2026
U.S. FDA approves DECNUPAZ for adult patients with BPDCN, a rare aggressive Blood cancer

Weekly Digest – May 2026 Weekly Digest – May 2026 27 May 2026: U.S. FDA approves DECNUPAZ for adult patients with BPDCN, a rare aggressive Blood cancer AbbVie has secured U.S. FDA approval for DECNUPAZ in blastic plasmacytoid dendritic cell […]

by Sandhya Ramalingam

Continue Reading
Approval  ·  Weekly Digest - 23 May to 29 May 2026
Datroway approved in the U.S. as first TROP2-directed ADC for 1L metastatic TNBC patients ineligible for PD-1/PD-L1 inhibitors

Weekly Digest – May 2026 Weekly Digest – May 2026 22 May 2026: Datroway approved in the U.S. as first TROP2-directed ADC for 1L metastatic TNBC patients ineligible for PD-1/PD-L1 inhibitors AstraZeneca and Daiichi Sankyo have secured U.S. FDA approval […]

by Sandhya Ramalingam

Continue Reading
« First‹ Previous34567891011Next ›Last »
Page 7 of 54


Contact:

  info@ciscientists.com

 +1-908-212-7484

Optimal Dose

For a subscription, please provide your email id